Pretargeted α Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-<b><i>N</i></b>,<b><i>N</i></b>′,<b><i>N</i></b>″,<b><i>N</i></b>‴-Tetraacetic Acid-Biotin - Concepedia

Concepedia

Publication | Closed Access

Pretargeted α Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-<b><i>N</i></b>,<b><i>N</i></b>′,<b><i>N</i></b>″,<b><i>N</i></b>‴-Tetraacetic Acid-Biotin

41

Citations

44

References

2004

Year

Zhengsheng Yao, Meili Zhang, Kayhan Garmestani, Donald B. Axworthy, Robert W. Mallett, Alan R. Fritzberg, Lou J. Theodore, Paul S. Plascjak, William C. Eckelman, Thomas A. Waldmann,

Clinical Cancer Research

Abstract

(213)Bi-DOTA-biotin, directed by the Pretarget method to tumor-targeted B3-SA, showed a therapeutic effect, although the therapeutic index was low. The source of the toxicity was most likely related to the renal toxicity.

References

	Year	Citations

Page 1